 |
|
|
| |
Positive Predictive Value of SVR4 in Patients Who Achieved SVR12 From Phase 2 and 3 Clinical Trials With Glecaprevir/Pibrentasvir
|
| |
| |
AASLD 2020 virtual Nov 11-16
Reported by Jules Levin
Edward Gane1, Victor de Ledinghen2, Douglas E Dylla3, Giuliano Rizzardini4, Mitchell L Shiffman5, Stephen T Barclay6,7, Jose Luis Calleja8, Zhenyi Xue3, Margaret Burroughs3, Julio A Gutierrez91University of Auckland, New Zealand; 2Centre d'Investigation de la Fibrose Hépatique, Bordeaux University Hospital, Pessac, France; INSERM U1053, Bordeaux University, Bordeaux, France; 3AbbVie Inc., North Chicago, Illinois, United States; 41st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milan, Italy; 5Liver Institute of Virginia, Bon Secours Mercy Health, Richmond, Virginia, United States; 6Life Sciences, Glasgow Caledonian University, Glasgow, Scotland; 7Gastroenterology, Glasgow Royal Infirmary, Glasgow, Scotland; 8Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro, Madrid, Spain; 9Scripps Center for Organ and Cell Transplantation, La Jolla, California, United States
|
| |
|
|
|
|
|
